Loading clinical trials...
Loading clinical trials...
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
Conditions
Interventions
TNP-2092 for injection
placebo
Locations
1
China
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Start Date
July 7, 2022
Primary Completion Date
February 24, 2023
Completion Date
February 24, 2023
Last Updated
May 1, 2024
Lead Sponsor
TenNor Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions